Fibrosis Staging
Fibrosis Staging - Related Videos
09:27
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
0 Views •
Cited by 11 •
2016
We describe a method to produce an animal model of liver fibrosis in the rat, and assess the degree of fibrosis by histological examination of the liver. The model can be used to study the development of liver disease as well as to test the efficacy of potential anti-fibrotic agents.
01:23
Cystic Fibrosis: Pathogenesis
0 Views •
2024
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body. CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
0 Views •
Cited by 1 •
2025
Mouse model of metabolic dysfunction-associated steatotic liver disease (MASLD) with metabolic dysfunction, hepatic gene expression changes, and liver histopathological alterations that resemble human MASLD, including fibrosis that progresses to advanced fibrosis stage 3. This model can be used in studies of MASLD pathophysiology and in pre-clinical studies of new therapies.
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
0 Views •
2025
This protocol demonstrates how the Src homology 2 domain-containing 5'-inositol phosphatase (SHIP)-deficient mouse model of Crohn disease (CD)-like ileal inflammation and fibrosis can be used to test novel therapeutics for CD.
14:56
Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiae
0 Views •
Cited by 19 •
2012
Attempts to express the cystic fibrosis transmembrane conductance regulator (CFTR) in Saccharomyces cerevisiae have, until now, yielded relatively low amounts of protein. This protocol and the associated reagents distributed via the Cystic Fibrosis Foundation should allow the preparation of milligram amounts of this 'difficult' eukaryotic membrane protein.
FAQs
Interpretation centers on two related processes: accumulation of extracellular matrix and remodeling of tissue architecture. A higher stage therefore represents more extensive structural change, not merely the presence of scar tissue. This distinction matters clinically because the stage helps connect tissue injury with estimated disease severity, expected prognosis, and the urgency or type of treatment considered.
Histologic examination evaluates biopsy samples to determine how extensively fibrotic tissue has accumulated within an organ. Because it examines tissue directly, this approach supports grading of extracellular matrix deposition and tissue remodeling. The resulting assessment can then contribute to disease staging, prognosis estimation, and decisions about treatment needs in the relevant chronic condition.
Fibrotic change occurs in multiple organs, but the clinical context and staging criteria are not identical across conditions. A framework used for chronic liver disease may therefore differ from one applied to kidney, lung, or heart disease. Recognizing this variation is essential for interpreting a reported stage correctly and avoiding inappropriate comparisons between unrelated diseases.
When appropriate, noninvasive imaging or biomarker-based tests can provide alternatives or complements to biopsy-based assessment. Their use allows clinicians to evaluate fibrotic burden without relying exclusively on tissue sampling. The suitable approach depends on the affected organ and clinical condition, because staging criteria and the interpretation of results vary across diseases.
Clinicians first relate the assessment to the affected organ and underlying disease, then select an appropriate approach, such as histologic examination of a biopsy or a noninvasive imaging or biomarker-based test. They interpret the findings using the relevant staging criteria and use the assigned stage to support prognosis, risk assessment, and management decisions.
The assigned stage helps distinguish different levels of disease severity and supports risk stratification, meaning the organization of patients according to expected risk. This information can guide therapeutic decisions and clarify treatment needs. In this way, staging connects evidence of tissue remodeling with a more consistent clinical assessment of how aggressively the condition may require management.
Consistent staging provides a framework for comparing fibrotic progression over time. Clinicians can use follow-up assessments, where appropriate, to evaluate whether treatment appears to slow progression rather than relying only on a single measurement. This longitudinal use makes staging relevant not only to initial risk assessment, but also to monitoring disease course and therapeutic effectiveness.